Amarin Pharmaceuticals Ireland Limited v. Omthera Pharmaceuticals Inc.
1:14-cv-00279
Overview
Parties
Movant
AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)
Represented By
6 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Defendant
Omthera Pharmaceuticals Inc. Operating Company
Represented By
2 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Plaintiff
Amarin Pharmaceuticals Ireland Limited NPE (University / Research)
Represented By
4 Attorneys ListedFish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 7 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8663662
Stable pharmaceutical composition and methods of using same
|
Filed: 2012-11-26
Issued: 2014-03-04
|
Active (6.0 yrs remaining)
Expires: 2032-11-26
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
8
Dispositive
7
Granted
0
Denied
0
Pending / Review
7
Motions by Category
Key Dispositive Motions & Rulings